194 related articles for article (PubMed ID: 29520981)
21. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Tanizawa Y; Kaku K; Araki E; Tobe K; Terauchi Y; Utsunomiya K; Iwamoto Y; Watada H; Ohtsuka W; Watanabe D; Suganami H;
Expert Opin Pharmacother; 2014 Apr; 15(6):749-66. PubMed ID: 24512053
[TBL] [Abstract][Full Text] [Related]
22. Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
Yoshida A; Matsubayashi Y; Nojima T; Suganami H; Abe T; Ishizawa M; Fujihara K; Tanaka S; Kaku K; Sone H
J Clin Endocrinol Metab; 2019 Sep; 104(9):3647-3660. PubMed ID: 30811541
[TBL] [Abstract][Full Text] [Related]
23. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Diabetes; 2020 Dec; 69(12):2619-2629. PubMed ID: 33004472
[TBL] [Abstract][Full Text] [Related]
24. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
Atageldiyeva K; Fujita Y; Yanagimachi T; Mizumoto K; Takeda Y; Honjo J; Takiyama Y; Abiko A; Makino Y; Haneda M
PLoS One; 2016; 11(6):e0157672. PubMed ID: 27327650
[TBL] [Abstract][Full Text] [Related]
25. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
26. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
27. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
Ikeda S; Takano Y; Cynshi O; Tanaka R; Christ AD; Boerlin V; Beyer U; Beck A; Ciorciaro C; Meyer M; Kadowaki T
Diabetes Obes Metab; 2015 Oct; 17(10):984-93. PubMed ID: 26179482
[TBL] [Abstract][Full Text] [Related]
28. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
Obata A; Kubota N; Kubota T; Iwamoto M; Sato H; Sakurai Y; Takamoto I; Katsuyama H; Suzuki Y; Fukazawa M; Ikeda S; Iwayama K; Tokuyama K; Ueki K; Kadowaki T
Endocrinology; 2016 Mar; 157(3):1029-42. PubMed ID: 26713783
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
[TBL] [Abstract][Full Text] [Related]
30. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.
Sawada Y; Izumida Y; Takeuchi Y; Aita Y; Wada N; Li E; Murayama Y; Piao X; Shikama A; Masuda Y; Nishi-Tatsumi M; Kubota M; Sekiya M; Matsuzaka T; Nakagawa Y; Sugano Y; Iwasaki H; Kobayashi K; Yatoh S; Suzuki H; Yagyu H; Kawakami Y; Kadowaki T; Shimano H; Yahagi N
Biochem Biophys Res Commun; 2017 Nov; 493(1):40-45. PubMed ID: 28928093
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Tobe K; Suganami H; Kaku K
J Diabetes Investig; 2018 Jul; 9(4):862-869. PubMed ID: 29032638
[TBL] [Abstract][Full Text] [Related]
32. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.
Katsuno K; Fujimori Y; Ishikawa-Takemura Y; Isaji M
Eur J Pharmacol; 2009 Sep; 618(1-3):98-104. PubMed ID: 19615995
[TBL] [Abstract][Full Text] [Related]
33. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
Huang CH; Huang YY; Hsu BR
Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
[TBL] [Abstract][Full Text] [Related]
34. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2021 Jan; 20(1):4. PubMed ID: 33397376
[TBL] [Abstract][Full Text] [Related]
35. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
36. Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Shigeno R; Horie I; Ando T; Abiru N; Kawakami A
Diabetes Res Clin Pract; 2016 Jun; 116():43-5. PubMed ID: 27321315
[TBL] [Abstract][Full Text] [Related]
37. Long-term low carbohydrate diet leads to deleterious metabolic manifestations in diabetic mice.
Handa K; Inukai K; Onuma H; Kudo A; Nakagawa F; Tsugawa K; Kitahara A; Moriya R; Takahashi K; Sumitani Y; Hosaka T; Kawakami H; Oyadomari S; Ishida H
PLoS One; 2014; 9(8):e104948. PubMed ID: 25170869
[TBL] [Abstract][Full Text] [Related]
38. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
39. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
[TBL] [Abstract][Full Text] [Related]
40. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
